@HighYieldUro

High-Yield Urology 2026: A Guideline-Based Review • Author @BenDropkin • Book https://xitter.cf/t.co/uc5GwDuFzO • Q Bank https://xitter.cf/t.co/oYQ9dxE128

Joined May 2021
  • Tweets263
  • Following4.8K
  • Followers2.5K
22Media
🚨🚨🚨 @HighYieldUro Q BANK is Now Live! 🚀 1500+ high-yield questions built for in-service and board exam prep 👉 get started: qbank.com/hyu 💸 group discount info: highyieldurology.com/pages/q… 👇 preview & example question below @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
🤖 Made with AI
1
11
3
41
7,930
🚨T-minus 5️⃣ weeks to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ prepare to ace your exam with @HighYieldUro 2026 📖 and Q-Bank 💻📱 highyieldurology.com/

High-Yield Urology

Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.

highyieldurology.com
1
7
471
⏳ 7️⃣ weeks to go until the @ameriurological In-Service and @uroonc OKAT exams!
High-Yield Urology
@HighYieldUroAug 24
🚨🚨🚨 @HighYieldUro Q BANK is Now Live! 🚀 1500+ high-yield questions built for in-service and board exam prep 👉 get started: qbank.com/hyu 💸 group discount info: highyieldurology.com/pages/q… 👇 preview & example question below @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
1
2
571
High-Yield Urology retweeted
Toni Choueiri, MD
@DrChoueiriSep 24
JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert
47
5
101
6,792
Outstanding work, @urogabe 👏
Andrew Gabrielson
@urogabeSep 22
Oral boards prep hasn't appreciably changed in decades, so I built MockUro, an AI examiner that walks you through ~250 canonical urology cases in Socratic Q&A format, grades your free-form answers across key domains, and adapts your study plan to your weak spots 🧵
1
5
1,216
High-Yield Urology retweeted
Amer. Urol. Assn.
@AmerUrologicalSep 7
❓ What's new in the 2026 AUA/SUO NMIBC Guideline? Last week, we released an amendment to the Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Guideline. In this brief video, guideline panel member Dr. Jeff Holzbeierlein highlights key updates, including revised risk classification and new treatment recommendations designed to help clinicians navigate the rapidly evolving non-muscle invasive bladder cancer treatment landscape. 🔗 Check out the guideline now: bit.ly/4xxuZHj
2
10
25
3,734
1️⃣1️⃣ weeks to go until the @AmerUrological In-Service Exam ⏳
High-Yield Urology
@HighYieldUroAug 24
🚨🚨🚨 @HighYieldUro Q BANK is Now Live! 🚀 1500+ high-yield questions built for in-service and board exam prep 👉 get started: qbank.com/hyu 💸 group discount info: highyieldurology.com/pages/q… 👇 preview & example question below @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
2
782
1
96
115
🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2026 📖🚀 highyieldurology.com/

High-Yield Urology

Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.

highyieldurology.com
1
1
4
1,120
High-Yield Urology retweeted
Toni Choueiri, MD
@DrChoueiriJul 31
JUST IN: @US_FDA approves LuPSMA (Pluvicto, @Novartis) in combination with androgen receptor pathway inhibitor (ARPI) in PSMA (+) metastatic hormone-sensitive prostate cancer. Approval based on PSMAddition trial (HR PFS 0.72), immature OS.
5
51
1
127
9,107
🚨KEYNOTE-B15/EV-304 @NEJM 🌎🌍🌏 808 pts w/ untreated cisplatin-eligible, cystectomy-eligible MIBC ➡️ perioperative enfortumab vedotin (ADC to Nectin-4) + pembro (PD-1🛑) vs. neoadjuvant gem/cis ➡️ cystectomy ➡️ 2yr EFS 79% vs 66% (P<.001), 2yr OS 87% vs 81% (P=.006), pCR 56% vs 33% (P<.001) ➡️ ⬆️G3+ AEs (76% vs 67%) ➡️ FDA-approved ✅ nejm.org/doi/full/10.1056/NE…

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer | NEJM

Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin–pembrolizum...

nejm.org
2
480
Best of luck to everyone getting ready to ace their @ABUrology written boards this week!
5
757
Load more